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Methods We conducted a systematic review and meta-analysis of studies reporting circulating IL-6 in AAA, and new investiga-
tions of the association between a common non-synonymous functional variant (Asp358Ala) in the IL-6R gene (IL6R)
and AAA, followed the analysis of the variant both in vitro and in vivo.
Inflammation may play a role in the development of abdominal aortic aneurysms (AAA). Interleukin-6 (IL-6) sig-
nalling through its receptor (IL-6R) is one pathway that could be exploited pharmacologically. We investigated
this using a Mendelian randomization approach.
Results Up to October 2011, we identified seven studies (869 cases, 851 controls). Meta-analysis demonstrated that AAA
cases had higher levels of IL-6 than controls [standardized mean difference (SMD) ¼ 0.46 SD, 95% CI ¼ 0.25–
0.66, I2 ¼ 70%, P ¼ 1.1 × 10–5 random effects]. Meta-analysis of five studies (4524 cases/15 710 controls) demon-
strated that rs7529229 (which tags the non-synonymous variant Asp358Ala, rs2228145) was associated with a lower
risk of AAA, per Ala358 allele odds ratio 0.84, 95% CI: 0.80–0.89, I2 ¼ 0%, P ¼ 2.7 × 10–11). In vitro analyses in lym-
phoblastoid cell lines demonstrated a reduction in the expression of downstream targets (STAT3, MYC and ICAM1)
in response to IL-6 stimulation in Ala358 carriers.
Conclusions A Mendelian randomization approach provides robust evidence that signalling via the IL-6R is likely to be a causal
pathway in AAA. Drugs that inhibit IL-6R may play a role in AAA management.
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Introduction
Abdominal aortic aneurysm (AAA) affects 2–5% of men and
,1% of women aged 65–74 years.1–3 Progressive dilatation of
the aorta increases the risk of rupture and surgical intervention
is indicated when the diameter reaches 5.5 cm.4 Currently there
are no recognized treatments to diminish aneurysm progression
at an early stage and a pharmacological treatment that targeted
the processes underlying aortic dilatation, as well as vascular
disease in general would provide an attractive adjunct to the sur-
veillance and surgery treatment paradigm. However, few if any
therapeutic targets have been validated in humans to date.
The major environmental exposures associated with AAA de-
velopment include male sex, advancing age, cigarette smoking, dys-
lipidaemia, and hypertension.5 There is also a genetic component
to the disease, with twin studies reporting heritability in the
region of 70%.6 Two recent genome-wide association studies
(GWAS) of AAA have reported robust associations with
common variants in DAB2IP and LRP17,8, while the chromosome
9p21.3 locus associated with coronary heart disease (CHD) also
shows a strong association with AAA9. These variants, however,
explain only a small proportion of the observed heritability sug-
gesting other contributory genetic mechanisms remain to be
discovered.
Interleukin-6 (IL-6) signalling is initiated by binding of IL-6 to its
receptor (IL-6R), which forms a dimer with the ubiquitously
expressed signal transducer glycoprotein-130 (gp-130). This, in
turn leads to the activation of the intracellular receptor-associated
kinases and downstream effects via the transcription factor STAT3.
Two forms of IL-6 signalling have been described, namely classical
and trans-signalling. In classical signalling, IL-6 binds the membrane
bound IL-6R (mIL-6R), which is expressed in hepatocytes and cells
of the innate immune system. In trans-signalling, IL-6 binds to the
circulating soluble IL-6R (sIL-6R), and this complex is capable of
binding to gp130 in a wide range of cell types. It has previously
been shown that the expression of IL-6 and downstream media-
tors of IL-6 signalling, such as STAT3, are greater in AAA than in
non-aneurysmal aortic tissue.10,11
A common non-synonymous sequence variant in IL6R
(p.Asp358Ala, rs2228145, also annotated as rs8192284) results
in an increased proteolytic cleavage of the mIL-6R.12 This variant
is strongly associated with higher levels of circulating IL-6 levels,
but importantly, lower levels of downstream products of IL-6 sig-
nalling, such as C-reactive protein and fibrinogen,12–15 suggesting
that it acts by the attenuation of signalling via the IL-6 receptor.
Furthermore, it was shown that this variant conferred protection
against CHD, prompting speculation that targeting the IL-6R in
CHD is a potentially novel preventative strategy.16 Whether or
not this is the case for AAA has not yet been evaluated.
In the present study, the primary hypothesis is that
pro-inflammatory signalling via the IL-6R plays a causal role in
AAA development. This was investigated using a Mendelian rand-
mization approach. First, a systematic review and meta-analysis of
the published literature was performed in order to establish the re-
lationship between circulating IL-6 levels and AAA. Secondly, novel
analysis of the association between the functional Asp358Ala IL6R
variant and AAA was performed. Finally, in vitro analyses were used
to investigate the mechanism by which this variant could protect
from cardiovascular disease.
Methods
Observational association between
interleukin-6 and abdominal aortic
aneurysms
Studies were identified using a two-stage search strategy following
PRISMA guidelines17 (Supplementary material online). In the first
stage, two electronic databases (MEDLINE and EMBASE) were
searched and in the second stage articles were identified by manually
searching references of articles identified in the first stage and review
articles. Authors of large epidemiological studies of AAA were also
approached to determine whether they had measures of IL-6 in
cases and controls. The MEDLINE database was searched from
January 1966 to January 2012, and the EMBASE from 1980 to
January 2012. Inclusion criteria were decided by consensus (SCH,
RR, MVH, and SEH), and the studies were screened and abstracted
in duplicate by SCH and RR. The search strategy is described in
detail in the Supplementary material online.
Study populations
Detailed descriptions of the study cohorts and demographic details are
presented in the Supplementary material online. Briefly, for the genetic
association analyses, we used data from five case–control studies of
AAA that have access to genetic information, and are part of an exist-
ing collaborative group investigating the genetics of AAA. All studies
defined AAA as an infra-renal aortic diameter ≥3 cm by ultrasound
or computed tomography imaging, or previous AAA rupture/repair.
The Aneurysm Consortium (AC) Genome Wide association Study
of Abdominal Aortic Aneurysm recruited 1596 cases of AAA from
centres across the UK and Western Australia. Control data were
taken from the Wellcome Trust Case Control Consortium (n ¼
5855). The New Zealand study included 1373 individuals with AAA
and 718 controls with no previous history of vascular disease7. The
Secondary Manifestations of ARTerial disease (SMART) study included
data from 631 cases of AAA and 6342 AAA free controls recruited
from University Medical Center Utrecht, the Netherlands. The Edin-
burgh Artery Study (EAS) is a prospective population-based cohort
that included data from 62 cases of AAA and 819 AAA free controls.18
In the Utrectht Study (separate from the SMART study), 862 indivi-
duals with AAA were recruited to the ‘genetics AAA’ study and com-
pared with controls from the ERGO/Rotterdam study (n ¼ 1866).19
Studies were identified as part of established collaborative efforts to
understand the genetics of AAA.8 All studies had full ethical approval.
Genotyping
Participants in the AC AAA GWAS were genotyped using the Illumina
660 k gene-chip, with previously described quality control filters. Indi-
viduals in the SMART study were genotyped using KASpar at KBios-
ciences, UK (www.kbioscience.co.uk). For the New Zealand study,
samples were genotyped using the TaqMan allelic discrimination
method (using a pre-designed, functionally tested assay Applied Biosys-
tems, assay C_26292282_10). For the Utrecht study, participants were
genotyped using the Illumina 610k Chip.
In the SMART study, rs7529229 was genotyped and in the
New Zealand study rs4129267 was genotyped. These SNPs are
perfect proxies for each other (R2 ¼ 1). These SNPs both tag the non-
synonymous variant (p.Asp358Ala, rs2228145, R2 ¼ 0.97). Linkage
S.C. Harrison et al.3708
 at U
CL Library Services on January 29, 2014
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
disequilibrium between SNPs was assessed using the SNP Annotation
and Proxy Search resources (www. broadinstitute.org/mpg/snap/).
Functional analysis of the p.Asp358Ala
(rs2228145) variant
Epstein Barr Virus-transformed lymphoblastoid cell lines were used
based on the genotype, confirmed using Taqman allelic discrimination
(Applied Biosystems). After RNA extraction, gene expression was ana-
lysed using Taqman Gene Expression Assays designed for targeting
STAT3, MYC, ATF3, ICAM1, and BCL3 (Applied Biosystems, Carlsbad,
USA) using a 384-well plate format, following the standard protocol
provided by Applied Biosystems. Full details of the in vitro methodology
are described in the Supplementary material online. These target genes
were chosen because they have been shown to be the major down-
stream target of IL-6—STAT3 signalling.20
Statistical analysis and power
To estimate the association between circulating IL-6 and AAA, we per-
formed meta-analysis of summary statistics identified by our systematic
review. For each study, we used mean concentrations of IL-6 in cases
and controls to determine a standardized mean difference (SMD) and
standard error. For studies that reported median concentration levels
and inter-quartile ranges (IQR), we took the median to be the mean
value and divided the IQR by 1.35 in order to obtain the SDs. Mean
differences in each study were pooled using inverse-weighted-
fixed-effect meta-analysis. Heterogeneity was assessed using the I2
statistic and Cochrane’s Q. Owing to heterogeneity in units used to
measure IL-6, and baseline levels, a SMD was calculated preferentially
to a weighted mean difference.
SNP-disease associations in each cohort were determined using
logistic regression adjusted for age and gender, under an additive
genetic model. Effects sizes are reported as odds ratios (OR) and
95% confidence intervals. Meta-analysis was performed using fixed
and random-effects modelling and we measured between study het-
erogeneity using the I2 statistic. Gene expression was analysed using
the Rest Expression Software Tool by MW Pfaffl utilizing a Pair-Wise
Fixed Reallocation Randomization Test. With 4523 case and 15 406
controls, there was over 80% to detect modest effects (OR . 1.12)
on disease risk with a Type 1 error rate of 1 in 1000.
Results
Systematic review and meta-analysis of
IL-6 and abdominal aortic aneurysms
Seven studies reporting circulating levels of plasma IL-6 in AAA
cases and controls were identified (Supplementary material
online, Figure S1), including one previous unpublished study (the
NZ study)21–27. Two studies that reported higher IL-6 in cases
than controls, but did not report summary measures of IL-6
(mean and SD or median and IQR) were not included in the
meta-analysis.27,28 Details of the studies included in the
meta-analysis are provided in Table 1. All identified studies utilized
a case–control design and used recognized methods to diagnose
and define the presence of AAA and to measure IL-6 levels. No
prospective population studies were identified. All but one
study21 selected controls that were matched for age and gender,
but only one study matched for smoking status, but none specific-
ally adjusted for these factors in the primary analyses. An
assessment of the quality of the case–control studies is provided
in Supplementary material online, Table S1.
In meta-analysis, pooling data from 869 cases and 851 controls,
individuals with AAA had higher circulating IL-6 concentrations
than controls; SMD ¼ 0.46, 95% CI: 0.25–0.66, P random effects
model ¼ 1. 1 × 1025, I2 ¼ 70%. Concentrations of IL-6 were
higher in cases than in controls in all but one of the studies in
which no difference was observed.26 This study included only
small AAA in the case group (3–5.5 cm), and reported different
measurement units to all the other studies (ng/mL vs. pg/mL). Ex-
clusion of this study reduced overall heterogeneity (I2 ¼ 56%) and
increased the statistical significance of the association (P random
effects ¼ 2 × 1028); however, this study did not overly influence
the overall effect estimate greatly (sensitivity analysis presented
in the Supplementary material online, Figure S2). Possible reasons
for heterogeneity may be related to the selection of cases and con-
trols. For example, there is evidence that IL-6 concentrations are
correlated with the AAA size22,25,29 and subgroups analyses
demonstrated that when the analysis was restricted to studies
that compared IL-6 in large AAA compared with controls, there
was less heterogeneity (I2 ¼ 31.5%, Figure 1). Furthermore, there
was variation in how controls were selected, e.g. from distinct
cohorts such as the general population23 or from surgical outpati-
ents clinics,26 which is likely to contribute to heterogeneity. There
was no evidence of publication bias using Begg’s adjusted rank cor-
relation test (P ¼ 0.7).
Association of IL6R variants with
abdominal aortic aneurysms
Demographic details of the five case–controls studies are shown
in Table 2 and genotyping quality control measures are shown in
Table 3. There was a consistent association between the rare
allele of rs7529229 (tagging Ala358) and reduced risk of AAA in
all cohorts. Meta-analysis, pooling data from 4524 cases and
15 710 controls demonstrated a per-allele OR of 0.84 (95% CI:
0.80–0.89, P ¼ 2.7 × 10211, I2 ¼ 0% fixed-effect meta-analysis)
(Figure 2). In time-to-event analyses of prospective data from the
SMART study, using Cox proportional hazard models, adjusted
for age and gender, the rare Ala358 allele was also associated
with a reduction in the risk of AAA clinical endpoints (AAA
rupture, repair, nevents ¼ 223) (Figure 3, per allele HR: 0.81, 95%
CI: 0.67–0.99, P ¼ 0.043).
Functional analyses of the Asp358Ala
(rs2228145) IL6R variant
The aim of these analyses was to determine the downstream
effects of the Asp358Ala variant on the expression of
IL-6-mediated target genes identified in previous studies,20
namely STAT3, MYC, BCL3, ICAM1, and ATF3.
In lymphoblastoid cells, no difference in the expression of
STAT3 targets was observed at baseline (Figure 4A). After IL-6
stimulation, there was a reduction in the expression of STAT3,
MYC, ICAM1 in Ala358 homozygotes (CC) compared with
Asp358 homozygotes (AA) (Figure 4B). This genotype-dependent
difference was abolished by the presence of excess sIL-6R in the
media (Figure 4C), suggesting that the effect observed with IL-6
Interleukin 6 receptor 3709
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Table 1 Characteristics of case–control studies included in the meta-analysis of IL-6 levels in abdominal aortic aneurysms cases and controls
Author Year Country Study design Cases/controls Case definition Controls Diagnosis IL-6 cases,
mean (SD)
IL-6 controls,
mean (SD)
Treska 2003 Czech Republic Case–Control 74/30 Small (,5 cm) ¼ 30
Large (5–8 cm) ¼ 38
Very large (.8 cm) ¼ 22
Ruptured/
symptomatic ¼ 16**
Matched for age and gender
No history of
atherosclerosis
USS 59.3 (134.8) 6.7 (5.1)
Fowkes et al.23 2006 UK Case–Control 89/98 AP aortic diameter .3 cm,
size distribution NR
Normal USS (,3 cm)
Matched for age and
gender. Nested case–
control within the
Edinburgh Artery Study18
USS 2.8 (1.62) 1.8 (1.04)
Dawson et al.21 2007 UK Case-Control 27/15 Large AAA undergoing
endovascular repair
Undergoing other vascular
intervention
CT 4.94 (2.49) 2.65 (1.98)
Flondell-Site 2009 Sweden Case–Control 360/218 Small (,4.5 cm) ¼ 122
Medium(4.5–
5.5 cm) ¼ 108
Large (.5.5 cm) ¼ 130
Age and sex matched
No history of
Atherosclerosis/AAA
Undergoing routine
preventative checks
CT/USS 9.19 (31.91) 2.08 (2.90)
Jones (unpublished) 2012 New Zealand Case–Control 166/359 All greater than 5 cm,
awaiting repair
Matched for age, free from
atherosclerosis and AAA.
Recruited from screening
programme in NZ.
CT/USS 9.1 (6.60) 6.3 (3.93)
Parry et al.26 2010 UK Case–Control 75/90 All AAA ,5.5 cm Matched for age, gender,
and race
Recruited from surgical
clinics
USS 3.13 (2.87) 3.14 (2.32)
Wallinder et al.25 2009 Sweden Case–Control
Case–Control
78/41 Small (,5 cm) ¼ 38
Awaiting elective repair
(.5 cm) ¼ 40
Matched for age, gender, and
smoking status
Volunteers with infra-renal
aortic diameter ,3 cm
USS 4.02 (3.79) 2.3 (3.3)
**Values from ruptures not included in the meta-analysis. S.C
.H
arrison
et
al.
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stimulation alone is via reducing signalling through the m-IL6R is
the presence of Ala358.
Discussion
In this study, we used an extension of the Mendelian randomisation
(MR) paradigm to investigate the potential utility of targeting IL-6
signalling in AAA. In the first stage, we reviewed the observational
literature reporting associations between circulating IL-6 and
the presence of AAA. Meta-analysis of case–control studies
demonstrated that IL-6 was significantly higher in subjects with
AAA compared with those without. These data support a hypoth-
esis that IL-6 and associated signalling pathways may play a role in
the development of AAA, but it is not possible to directly infer a
causal relationship, from observational data associations alone,
owing to limitations inherent in such analyses. For example,
many of the studies did not adjust for potential confounders
such as smoking status, and previously published reports have
found that AAAs are a source of circulating IL-6,21 suggesting
that the observed association could at least in part be the result
of reverse causation. Furthermore, none of the identified studies
was prospective population cohorts, considered the gold standard
Figure 1 Association between circulating IL-6 levels and the presence of abdominal aortic aneurysms. In pooled analysis of seven studies
reporting IL-6 circulations in cases and controls (869/851) there was consistently higher concentrations in cases (SMD ¼ 0.46, 95% CI:
0.25–0.66, P random effects model ¼ 1. 1 × 1025, I2 ¼ 70%). Subgroup analyses, comparing IL-6 concentrations in large abdominal aortic
aneurysms (.5 cm) demonstrated less heterogeneity (SMD ¼ 0.46, 95% CI: 0.34–0.58, P ¼ 2.25 × 10214, I2 ¼ 32%).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Demographic details of cohorts used for gene association analysis
Controls Cases
Sample set ncontrols % Female Age (SD) ncases % Female Age (SD)
AC 5855 50 NA 1596 4 NA
SMART 6352 33 55 (12) 631 22 65 (10)
NZ 718 23 70 (6.6) 1373 20 74 (8.0)
EAS 819 47 64 (5.6) 62 66 (5.6) 74
UTRECHT 1866 56 56 862 10 68.1 (8.3)
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in epidemiological studies and there was some heterogeneity in
how cases and controls were selected in the papers identified by
the literature search.
To address this, we applied the principles of MR for drug target
validation by studying the association between a functional non-
synonymous variant in IL6R and AAA. Genotype is randomly allo-
cated at conception and not subject to reverse causality and there-
fore represents a useful tool to examine causal relationships in
complex diseases phenotypes. The Asp358Ala variant (or close
proxy) was selected because it has previously been shown that it
has concordant effects as tocilizumab on a range of inflammatory
and cardiovascular biomarkers and, therefore, may be considered
a useful genetic instrument to investigate the potential for targeting
the IL-6R pharmacologically.30 There was a consistent association
between the Ala358 variant and a reduced risk of AAA, a finding
that suggests targeting the IL-6R is a plausible strategy in AAA.
This was a statistically robust association, surpassing threshold
levels of significance commonly used in genome-wide studies.
The IL6R variants have not been previously identified in two sep-
arate GWAS of AAA7,31; however, the largest of the discovery
cohorts (ncases ¼ 1866) had only 20% power to detect a variant
of this effect size at the significance threshold of P, 1 × 1025
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Genotyping metrics from each of the studies (Hardy–Weinberg equilibrium)
Study Genotyping platform Minor allele frequency Call rate (%) HWE, P-value
AC Illumina 670 k Beadchip 0.39 .99 0.28
New Zealand ABI Taqman 0.40 .98 0.89
SMART Kaspar 0.39 .97 0.77
EAS ABI Taqman 0.42 .97 0.08
UTRECHT Illumina 610 K 0.38 100 0.97
Figure 2 Association between rs7529229 and abdominal aortic aneurysms following fixed-effect meta-analysis of four case–control studies
(4524 cases/15 710 controls). Per allele odds ratio ¼ 0.84 (95% CI: 0.80–0.89, I2 ¼ 0, P ¼ 2.7 × 10211).
Figure 3 Time to event analysis curves showing the probability
of abdominal aortic aneurysm-related endpoint (Rupture/Endo-
vascular Repair/Open Repair) by genotype at rs7529229 (CC is
the rare homozygote) in 7139 individuals from the SMART
study, in who there were 223 events. The hazard ratio per
C-allele is 0.81, 95% CI ¼ 0.67–0.99, P ¼ 0.043.) The P-value
was calculated using Cox regression, adjusting for age and gender.
S.C. Harrison et al.3712
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used to triage those SNPs to be submitted for analysis in replica-
tion studies.
Given the higher levels of circulating IL-6 in patients with AAA, it
may seem paradoxical that a variant associated with higher circulat-
ing IL-6 is also associated with a lower risk of AAA. However, this
variant has previously been associated with reduced concentra-
tions of C-reactive protein and fibrinogen (two downstream
markers of IL6R activation), a pattern consistent with a pharmaco-
logical blockade of the IL-6 receptor with tocilizumab30. Further-
more, it is important to note that this study is not an MR study
of circulating IL-6 and AAA, but uses the MR concept to evaluate
the potential utility of targeting the IL-6R in AAA disease.
The functional analysis suggests that the Ala358 variant is asso-
ciated with a reduction in the sensitivity of immune cells to IL-6 in
vitro. One possible interpretation of these data is that this variant
reduces inflammation in the aortic wall in response to injury, via
reduced signalling through the mIL-6R in immune cells recruited
to the injury, resulting in a lower risk of AAA development. Al-
though the lymphoblastoid cell line is useful to understand the
functional consequences of this variant in vitro, further work on
Figure 4 Gene expression in STAT3 target genes in lymphoblast cell lines of different IL6R rs2228145 (AA ¼ common homozygote; CC,
rare homozygote). (A) Basal gene expression in lymphoblast cell lines shows no difference in gene expression between IL6R genotypes. (B)
Gene expression following IL-6 stimulation; lower gene expression was observed in all STAT3 target genes in lymphoblasts possessing the
C allele. (C) Gene expression following IL-6 stimulation and addition of excess sIL-6R. To examine if the effect seen in (B) was due to receptor
shedding, excess soluble IL-6R was added to the stimulated cells, suggesting that the mechanism is of genotype-specific reduction in STAT3
targets is the result of increased shedding of the mIL-6R.
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tissue specifically from AAA cases required to understand the in
vivo mechanism of action, particularly in understating the balance
of pro- and anti-inflammatory effects on remodelling of the arterial
wall in response to damaging environmental exposures that
promote vascular injury.
These findings have potentially important translational implica-
tions as they support a hypothesis that targeting the IL-6R pharma-
cologically is a strategy that merits evaluation in AAA. No
randomized trials of tocilizumab (a monoclonal antibody to the
IL6R used to treat rheumatoid arthritis) have yet examined AAA
as an outcome, although two recent open label studies have
reported that in patients with rheumatoid arthritis, tocilizumab
reduces arterial stiffness,32,33 which suggests that the IL6R block-
ade has effects on the vasculature. Indeed, a role for tocilizumab
in the treatment of other forms of inflammatory vascular disease
such as Takayasu’s arteritis has been postulated, although rando-
mized trials in these conditions have not yet been reported.34 Fur-
thermore, there is evidence that targeting inflammatory pathways
can both prevent aneurysm formation and regress already estab-
lished aneurysms35 in murine models of the disease and evidence
that tocilizumab acts on this pathway.36 Tocilizumab does,
however, have a number of side effects (such as hypersensitivity
and respiratory tract infections) and the potential for benefit in
patients with AAA would of course need to be balanced against
the potential risks.
Although the effect of the IL6R Asp358Ala variant on AAA risk is
modest, the potential for clinical benefit from pharmacological
intervention at the IL-6R should not be discounted. For example,
SNPs in HMGCR (the target for statins) show only a modest (but
highly significant) effect on CHD risk, but the role of statins in
the prevention of CHD is well established.37,38 The fact that toci-
lizumab has been shown to be safe in large trials in humans adds
further weight to the translational potential of the present findings.
In common with two of the three previously identified well-
validated loci associated with risk of AAA the IL6R locus is also
associated with CHD.13,16,30,39 The magnitude of the effect identi-
fied in the present analysis (OR: 0.86, 95% CI: 0.80–0.89) is,
however, greater than that reported for the association with
CHD risk (OR: 0.95).30,39 The association with CHD does,
however, strengthen the case for targeting the IL-6R therapeutic-
ally, as the major non-aneurysm-related cause of death in patients
with dilated aortae is cardiovascular disease.40
Limitations
It is important to note the potential limitations of this study. The
number of cases and controls identified from the published litera-
ture for the case–control analysis of IL-6 levels and AAA is rela-
tively small, but effects were consistent and the overall result
statistically robust. We did not have tissue from AAA for expres-
sion studies. The in vitro functional studies are in a lymphoblastoid
cell-line, which may not mimic the in vivo immune response in the
aortic wall. As there was limited phenotypic/risk factor data for
some of the cohorts, we were unable to include the IL6R variant
in a multivariate regression model including other covariates.
However, no convincing effect on phenotypes such as smoking,
lipids, and blood pressure has been seen in large-scale association
analysis suggesting that the effects are not primarily mediated
through, or confounded by these intermediate phenotypes.
Finally, we would ideally have a large data set with validated mea-
sures of aortic expansion in the context of the IL6R genotype and
assess whether or not this could provide clinically useful informa-
tion to guide surveillance programmes, but this is not available at
present.
Conclusion
This study has confirmed that AAA cases have higher concentra-
tions of circulating IL-6 than controls, and provided novel evidence
that a common functional variant in IL6R is associated with risk of
AAA. This provides evidence that targeting the IL-6R may be a
useful and novel strategy in AAA, and supports development of
clinical trials in this regard.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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